Bli medlem
Bli medlem

Du är här

2017-02-06

DBP: Promising results for Temodex, drug candidate against brain cancer, after completion of the first MGMT study

Preliminary results indicate that there is no significant difference
in survival between MGMT methylation-positive and negative patients
treated with Temodex, and that all patients who received Temodex had
a significantly better survival than the control group when both DNA
and protein data for MGMT were taken into account. This result will
later this year be presented at scientific meetings and in scientific
journals. Further studies on a larger group of patients are scheduled
to start shortly.

"MGMT status permits to distinguish patients who respond well or
respond poorly to standard-of-care chemotherapy with temozolomide.
That MGMT status does not seem to be as critical for patient survival
after treatment with Temodex in combination with standard treatment
can mean that Temodex has a chance to become the most effective
chemotherapeutic treatment for patients who respond poorly to
standard therapy with temozolomide, "- says Dr. Iulia Karlsson, Head
of Biomarker and Companion Diagnostics Development in DBP.

"This study creates a very strong profile for Temodex and gives us
great opportunities ahead to continue our development toward making
Temodex a new effective drug against brain cancer", - says Igor
Lokot, CEO of Double Bond Pharmaceutical.

This information is information that DBPI AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 6th of February 2017.

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Blogg: http://blog.doublebp.com

Follow us on LinkedIn
(https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-...)
and Twitter (https://twitter.com/DoubleBondPharm)!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development
of therapies against cancer based on the company's own developed drug
delivery technology BeloGal®. The company was granted Orphan Drug
Designation status by European Medicines Agency (EMA) in June 2015
for its first product, SA-033, for treatment of hepatoblastoma. DBP
acquired rights to Temodex, a drug registered in Belarus for
treatment of brain tumours, in October 2015. The company was granted
Orphan Drug Designation status by EMA for Temodex in July 2016.

-----------------------------------------------------------
http://news.cision.com/dbp/r/promising-results-for-temodex--drug-candida...
http://mb.cision.com/Main/12720/2180436/624023.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.